Mount Sinai-led study in Diabetologia shows PAL-119 stimulated human beta cell proliferation and enhanced markers of beta cell function
Findings support development of PAL-119 as an investigational, disease modifying oral therapy for Type 1 and Type 2 diabetes
SAN DIEGO, Nov. 18, 2026 /PRNewswire/ -- Paulex Bio Inc., a biopharmaceutical company focused on rebuilding the body's own insulin-producing capacity, today highlighted peer-reviewed research published in Diabetologia supporting PAL-119, its investigational oral therapy designed to regenerate and restore the function of insulin-producing beta cells in diabetes. The study, led by researchers at the Icahn School of Medicine at Mount Sinai, provides evidence that increasing beta cell numbers and enhancing the specialized characteristics needed for insulin production involve distinct biological mechanisms. PAL-119, identified in the publication as 2-2c, was one of only three of the seven DYRK1A inhibitors tested that both stimulated human beta cell proliferation and increased expression of markers associated with beta cell identity and function.
The paper, "Harmine selectively enhances human beta cell identity markers and function via protein kinase A pathways" (DOI: 10.1007/s00125-026-06857-5), examined how different inhibitors of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) affect human pancreatic islets. All seven inhibitors tested stimulated human beta cell proliferation, but only three, including PAL-119, also enhanced markers associated with the specialized characteristics that enable beta cells to produce insulin and respond to glucose. The authors attribute these additional effects of PAL-119 and the two other dual-acting compounds to a second target, independent of DYRK1A, that engages the protein kinase A (PKA) pathway. Using an affinity probe derived from PAL-119, the researchers identified the PKA regulatory subunit PRKAR1A as the lead candidate among proteins captured from human islets. The authors concluded that DYRK1A inhibitors are not interchangeable and that those that drive both beta cell proliferation (regeneration, proposed to be mediated by DYRK1A) and identity and function (restoration of function, proposed to be mediated by PKA) will likely be preferable for diabetes therapy.
Of the three dual-acting compounds, only PAL-119 is being developed as a drug candidate; the other two, harmine and 5-iodotubercidin, are not suitable for development as drugs. Harmine is a naturally occurring plant product with well-documented off-target activity, including undesired effects on the central nervous system resulting from its ability to cross the blood-brain barrier and enter the brain. 5-Iodotubercidin is a genotoxic nucleoside analog used as a laboratory research tool.
Loss and dysfunction of insulin-producing beta cells are central to both Type 1 and Type 2 diabetes. Current medicines can replace insulin and improve the body's response to it or stimulate insulin secretion. However, regenerating the patient's own beta cells remains an unmet therapeutic opportunity in both forms of the disorder. The findings support a development approach that seeks to increase beta cell numbers while enhancing their functional characteristics.
"Our goal is to rebuild the body's own insulin-producing capacity by regenerating beta cells and enhancing the function that allows them to respond appropriately to glucose," said Miguel Sanjuan, Ph.D., Co-Founder, President and CEO of Paulex Bio. "This research strengthens the scientific rationale for pursuing both objectives with PAL-119. Building on Mount Sinai's foundational work in beta cell regeneration, PAL-119 was engineered to be highly target specific and to have a substantially reduced ability to cross the blood-brain barrier, the natural barrier that protects the brain. To our knowledge, PAL-119 is the only DYRK1A inhibitor in development shown both to regenerate beta cells and to enhance their function. We are advancing this approach toward clinical testing with the ambition of changing the course of diabetes and, ultimately, achieving a functional cure."
PAL-119 is an oral small molecule designed to regenerate beta cells through DYRK1A inhibition and enhance beta cell function through PKA-associated signaling. These complementary, dual-action mechanisms offer the potential to both increase the number of functional beta cells and augment the body's ability to produce insulin in response to glucose. Paulex is advancing a Phase 1/2a program to evaluate PAL-119's safety, tolerability and pharmacokinetics and explore its effects on beta cell function, including measures of the body's own insulin production.
About PAL-119
PAL-119 is an investigational, dual-action oral small molecule designed to regenerate and restore the function of insulin-producing beta cells, with potential applications in Type 1 and Type 2 diabetes. Originating from research at the Icahn School of Medicine at Mount Sinai, PAL-119 acts to increase beta cell numbers through DYRK1A inhibition and enhance beta cell function through PKA-associated signaling. PAL-119 was engineered to overcome the liabilities of harmine, with improved target selectivity and substantially reduced brain exposure.
About Paulex Bio
Paulex Bio Inc. is a biopharmaceutical company focused on changing the course of diabetes by addressing the biological cause of the disease. Its lead candidate, PAL-119, is an investigational oral small molecule designed to regenerate and restore the function of insulin-producing beta cells, with potential applications in Type 1 and Type 2 diabetes. Paulex holds exclusive worldwide rights from the Icahn School of Medicine at Mount Sinai to PAL-119 and related compounds, including composition-of-matter patent families. For more information, visit www.paulexbio.com.
Forward-Looking Statements
This release contains forward-looking statements regarding Paulex Bio's research and development programs, including the potential benefits of its investigational therapies and the timing, progress and results of clinical trials. These statements reflect current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to clinical development, regulatory requirements, financing and the company's ability to advance its programs. Paulex Bio undertakes no obligation to update these statements, except as required by law.
Contacts
Tiberend Strategic Advisors, Inc.
Investor Relations
David Irish / Brooke Cooper
231-632-0002 / 862-274-1134
[email protected] / [email protected]
Media Relations
Eric Sagonowsky / Michelle Katsel
734-904-8887/ 201-790-3390
[email protected] / [email protected]
SOURCE Paulex Bio Inc.

Share this article